Search

Your search keyword '"Fagret, Daniel"' showing total 258 results
Start Over Author "Fagret, Daniel" Language english
258 results on '"Fagret, Daniel"'

2. Regional CZT myocardial perfusion reserve for the detection of territories with simultaneously impaired CFR and IMR in patients without obstructive coronary artery disease: a pilot study

Author

Djaïleb, Loïc, De Leiris, Nicolas, Canu, Marjorie, Sy, Olivier Phan, Seiller, Alexandre, Leenhardt, Julien, Charlon, Clémence, Faure, Marine, Caillard, Jessica, Broisat, Alexis, Borel, Anne-Laure, Lablanche, Sandrine, Betry, Cécile, Ghezzi, Catherine, Vanzetto, Gérald, Fagret, Daniel, Riou, Laurent M., and Barone-Rochette, Gilles

Published
2023
Full Text
View/download PDF

3. Comparison of Cadmium Zinc Telluride ECG-gated SPECT equilibrium radionuclide angiocardiography to magnetic resonance imaging to measure right ventricular volumes and ejection fraction in patients with cardiomyopathy

Author

Apert, Antoine, Canu, Marjorie, Jankowski, Adrien, Riou, Laurent, Broisat, Alexis, Charlon, Clemence, Augier, Caroline, Boignard, Aude, Leenhardt, Julien, Salvat, Muriel, Casset, Charlotte, Maurin, Marion, Saunier, Carole, Vanzetto, Gerald, Fagret, Daniel, Ghezzi, Catherine, Djaileb, Loic, and Barone-Rochette, Gilles

Published
2022
Full Text
View/download PDF

16. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.

Author

Echavidre, William, Fagret, Daniel, Faraggi, Marc, Picco, Vincent, and Montemagno, Christopher

Subjects
*RADIOISOTOPE therapy, *INDIVIDUALIZED medicine, *RADIOISOTOPES, *DIAGNOSTIC imaging, *TREATMENT effectiveness, *NEUROENDOCRINE tumors, *SOMATOSTATIN, *RADIOPHARMACEUTICALS, *NUCLEAR medicine, *COMBINED modality therapy, *IMMUNOTHERAPY, *PROSTATE tumors
Abstract

Simple Summary: This review summarizes recent advances in the nuclear medicine theranostic approach. It covers the repurposing of historical radiotracers for new indications and highlights new radiotracers in solid malignancies. Additionally, the potential of combining theranostics with immunotherapy is explored, underscoring the promise of personalized and targeted therapies. The progress in theranostics signifies an exciting era in nuclear medicine with potential benefits for diverse cancer types. The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Coronary Physiology: Delivering Precision Medicine?

Author

Maitre-Ballesteros, Laura, Riou, Laurent, Marliere, Stephanie, Canu, Marjorie, Vautrin, Estelle, Piliero, Nicola, Ormezzano, Oliviez, Bouvaist, Helene, Broisat, Alexis, Ghezzi, Catherine, Fagret, Daniel, Vanzetto, Gérald, Djaïleb, Loïc, and Barone-Rochette, Gilles

Abstract

Coronary physiological assessment is now widely used to assess epicardial coronary lesions in cath lab. Based on clinical evidence, fractional flow reserve (FFR) is the gold standard method to select whether epicardial coronary lesions need revascularization. While additional epicardial indexes, such as instantaneous wave-free ratio (iFR), are also used for revascularization decision-making, several indexes are now also available to explore the coronary microcirculation. Therefore, coronary physiological assessment now allows to explore the entire coronary tree and offer the potential of precision medicine for patients affected by coronary artery disease (CAD). This paper will provide review of the epicardial and microvascular indexes available for the assessment of coronary physiology. More specifically, the already demonstrated contributions of these indexes in the management of CAD and the role they could play in precision medicine will be reviewed with special emphasis on chronic coronary syndrome. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Tc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma

Author

Montemagno, Christopher, Cassim, Shamir, Trichanh, Dimitry, Savary, Clara, Pouysségur, Jacques, Pagès, Gilles, Fagret, Daniel, Broisat, Alexis, Ghezzi, Catherine, Centre Scientifique de Monaco (CSM), Radiopharmaceutiques biocliniques (LRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Nice Sophia Antipolis (... - 2019) (UNS), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], noninvasive imaging, endocrine system diseases, Mesothelin, [SDV]Life Sciences [q-bio], PDAC, digestive system diseases
Abstract

International audience; Mesothelin is a membrane-associated protein overexpressed in pancreatic ductal adenocarcinoma (PDAC). Some mesothelin-targeted therapies are in clinical development but the identification of patients eligible for such therapies is still challenging. The objective of this study was to perform the imaging of mesothelin in mice models of PDAC with a technetium-labeled anti-mesothelin single-domain antibody (Tc-A1).

Published
2019

50. Evaluation of antiatherogenic properties of ezetimibe using 3H-labeled low-density-lipoprotein cholesterol and 99mTc-cAbVCAM1-5 sPECT in ApoE2/2 mice fed the paigen diet

Author

Dumas, Laurent S, Briand, François, Clerc, Romain, Brousseau, Emmanuel, Montemagno, Christopher, Ahmadi, Mitra, Bacot, Sandrine, Soubies, Audrey, Perret, Pascale, Riou, Laurent M, Devoogdt, Nick, Lahoutte, Tony, Baronne-Rochette, Gilles, Fagret, Daniel, Ghezzi, Catherine, Sulpice, Thierry, Broisat, Alexis, Translational Imaging Research Alliance, Medical Imaging, and Supporting clinical sciences

Subjects
drug monitoring, Mice, Knockout, Tomography, Emission-Computed, Single-Photon, Atherosclerosis/diagnostic imaging, mice, Ezetimibe/administration & dosage, Mice, Transgenic, Cholesterol, LDL, Diet, High-Fat, Tritium, Sensitivity and Specificity, Mice, Inbred C57BL, Feces, Treatment Outcome, Anticholesteremic Agents/administration & dosage, Isotope Labeling, Animals, lipids (amino acids, peptides, and proteins), Female, reproducibility of results, technetium, Apolipoproteins E/genetics
Abstract

The addition of ezetimibe, an intestinal cholesterol absorption inhibitor, to statin therapy has recently shown clinical benefits in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more than statin therapy alone. Here, we investigated the mechanisms by which inhibition of intestinal cholesterol absorption might contribute to the clinically observed reduction in cardiovascular events by evaluating its effect on inflammatory plaque development in apolipoprotein E2/2 mice. Methods: Apolipoprotein E2/2 mice were fed the Paigen diet (1.25% cholesterol, 0.5% cholic acid, and 15% fat) without or with ezetimibe (7 mg/kg/d) for 6 wk. In a first set of mice (n 5 15), we intravenously injected 3H-cholesteryl oleate-labeled human LDL to test whether ezetimibe promotes LDL-derived cholesterol fecal excretion. In a second set (n 5 20), we used the imaging agent 99mTc-cAbVCAM1-5 to evaluate expression of an inflammatory marker, vascular cell adhesion molecule 1 (VCAM-1), in atherosclerotic plaques. In a third set (n 5 21), we compared VCAM-1 expression with 99mTc-cAbVCAM1-5 uptake in various tissues. Results: Mice treated with ezetimibe showed a 173% higher LDL-cholesteryl ester plasma disappearance rate (P , 0.001 vs. control) after 3H-cholesteryl oleate-labeled LDL injection. At 96 h after injection, the hepatic fraction of 3H-tracer was 61% lower in mice treated with ezetimibe (P , 0.001). Meanwhile, LDL-derived 3H-cholesterol excretion in the feces was 107% higher (P , 0.001). The antiatherogenic effect of ezetimibe monitored by 99mTc-cAbVCAM1-5 SPECT showed a 49% reduction in aortic tracer uptake (percentage injected dose per cubic centimeter, 0.95 6 0.04 vs. 1.87 6 0.11; P , 0.01). In addition to hypercholesterolemia, the proinflammatory Paigen diet significantly increased VCAM-1 expression with respect to the control group in various tissues, including the aorta, and this expression correlated strongly with 99mTc-cAbVCAM1-5 uptake (r 5 0.75; P , 0.05). Conclusion: Inhibition of intestinal cholesterol absorption with ezetimibe promotes antiatherosclerotic effects through increased LDL cholesterol catabolism and LDL-derived cholesterol fecal excretion and reduces inflamed atherosclerotic plaques. These mechanisms may contribute to the benefits of adding ezetimibe to a statin therapy.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results